P015 Breast Cancer patient selection for Extended Endocrine Therapy in the IDEAL trial by the 70-gene MammaPrint Test can prevent overtreatment and associated adverse events

P015 Breast Cancer patient selection for Extended Endocrine Therapy in the IDEAL trial by the 70-gene MammaPrint Test can prevent overtreatment and associated adverse events

Bibliographic Details
Main Authors:	G.-J. Liefers, E. Meershoek-Klein Kranenbarg, M. Duijm-de Carpentier, C.J. van de Velde, M. Kleijn, C. Dreezen, A. Menicucci, L. van’t Veer, W. Audeh
Format:	Article
Language:	English
Published:	Elsevier 2023-03-01
Series:	Breast
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977623001340

Similar Items

Comparing MammaPrint and BluePrint results between core needle biopsy and surgical resection breast cancer specimens
by: M. Kleijn, et al.
Published: (2021-04-01)

Prognostic Value of MammaPrint in Invasive Lobular Breast Cancer
by: Inès J. Beumer, et al.
Published: (2016-01-01)

Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer
by: Inès J. Beumer, et al.
Published: (2016-12-01)

MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial
by: Hatem Soliman, et al.
Published: (2020-01-01)

MammaPrint, BluePrint, and full-genome data linked with clinical data to evaluate new gene EXpression profiles (FLEX): a real-world dataset and investigator-initiated protocols in ESBC
by: J.A. Crozier, et al.
Published: (2021-04-01)

5-yr DMFS outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial
by: E. Göker, et al.
Published: (2021-04-01)

P157 MammaPrint 8-year follow up results in patients with early breast cancer from a single-center Italian cohort study
by: E. Fiorino, et al.
Published: (2023-03-01)

The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
by: Ettienne J. Myburgh, et al.
Published: (2021-10-01)

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer
by: Annuska M Glas, et al.
Published: (2010-11-01)

Biological Functions of the Genes in the Mammaprint Breast Cancer Profile Reflect the Hallmarks of Cancer
by: Sun Tian, et al.
Published: (2010-01-01)

RE: The cost impact of unselective vs selective MammaPrint testing in early-stage breast cancer in Southern Africa
by: Fabio Postiglione Mansani, et al.
Published: (2022-04-01)

A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
by: Young Joo Lee, et al.
Published: (2021-12-01)

MammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.
by: Andreas Bösl, et al.
Published: (2017-01-01)

Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and BluePrint® Kit at University Hospitals Leuven and Curie Institute Paris
by: Laurence Slembrouck, et al.
Published: (2019-12-01)

Validation study of a nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
by: Young Sol Hwang, et al.
Published: (2022-12-01)

Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
by: Alberto Peláez-García, et al.
Published: (2017-01-01)

A framework to predict the applicability of Oncotype DX, MammaPrint, and E2F4 gene signatures for improving breast cancer prognostic prediction
by: Kevin Yao, et al.
Published: (2022-02-01)

Nomogram prediction of the 70-gene signature (MammaPrint) binary and quartile categorized risk using medical history, imaging features and clinicopathological data among Chinese breast cancer patients
by: Bo Pan, et al.
Published: (2023-11-01)

Overtreatment
by: Marco Bobbio, et al.
Published: (2015-05-01)

P166 Budget impact of MammaPrint® in Patients with primary hormone receptor-positive, HER2-negative and non-metastatic early-stage breast cancer in France
by: D. Zarca, et al.
Published: (2023-03-01)

MammaPrint risk score distribution in South African breast cancer patients with the pathogenic BRCA2 c.7934delG founder variant: towards application of genomic medicine at the point-of-care
by: I. Mampunye, et al.
Published: (2021-04-01)

Overtreatment in the United States.
by: Heather Lyu, et al.
Published: (2017-01-01)

Merleaus mamma
by: Ina Hallström
Published: (2020-12-01)

Invasive Breast Cancer with HER2 ≥4.0 and <6.0: Risk Classification and Molecular Typing by a 21-Gene Expression Assay and MammaPrint Plus BluePrint Testing
by: Bai Q, et al.
Published: (2023-08-01)

Overdiagnosis and overtreatment in cancer screening
by: Stefano Ciatto
Published: (2010-03-01)

Gleason score 6: Overdiagnosis and overtreatment?
by: Yaxiong Tang, et al.
Published: (2023-06-01)

Overtreatment in rheumatoid arthritis: are there reasons for concern?
by: Laure Gossec, et al.
Published: (2022-10-01)

The overtreatment of illusory May Thurner syndrome
by: Paolo Zamboni, et al.
Published: (2019-01-01)

Overtreatment in treatment of cervical intraepithelial lesions
by: N. Kashtalian, et al.
Published: (2018-11-01)

Undertreatment or Overtreatment With Statins: Where Are We?
by: Irene García-Fernández-Bravo, et al.
Published: (2022-04-01)

Overtreatment in treatment of cervical intraepithelial lesions
by: N. Kashtalian, et al.
Published: (2018-11-01)

Overtreatment and undertreatment: time to challenge our thinking
by: Kearney, M, et al.
Published: (2017)

Reducing Overtreatment of Urinalysis in Obstetric Triage Patients
by: Emelia Winston, et al.
Published: (2020-07-01)

Angioleiomyosarcoma of mamma. Presentation of a case.
by: Lidia Torres Ajá
Published: (2006-08-01)

Phyllodes Tumor of the Mamma. Case Report
by: Lidia Torres Aja, et al.
Published: (2015-05-01)

La Mamma di Harald Szeemann
by: Pietro Rigolo
Published: (2022-10-01)

Mamma Mia, A Singable Translation!
by: Andrej Stopar
Published: (2016-06-01)

Phyllodes Tumor of the Mamma. Case Report
by: Lidia Torres Aja, et al.
Published: (2015-05-01)

Angioleiomyosarcoma of mamma. Presentation of a case.
by: Lidia Torres Ajá
Published: (2006-08-01)

Can Molecular Biomarkers Help Reduce the Overtreatment of DCIS?
by: Ezra Hahn, et al.
Published: (2023-06-01)